

**Listing of Claims:**

1. (Currently amended) A matrix transdermal system comprising about 3-20 % (m/m) (21S)-21-hydroxy-21-methyl-14, 17-ethano-19-norpregna-4,9,15-triene-3,20-dione, and dissolved in a matrix comprising polyacrylate adhesive,  
and having a transdermal skin flow rate of >100 ng/cm<sup>2</sup>/h between 10 h and 42 h as determined in a Franz-flow cell.
2. (Previously Presented) A transdermal system according to claim 1, wherein the polyacrylate adhesive is a copolymer of at least two of the following monomers: 2-ethylhexylacrylate, hydroxyethylhexylacrylate, vinyl acetate, or vinyl pyrrolidone.
3. (Previously Presented) A transdermal system according to claim 2, wherein the polyacrylate adhesive is a copolymer that consists of 2-ethylhexylacrylate and hydroxyethylacrylate or a copolymer of these monomers with vinyl acetate and 2-ethylhexylacrylate-N-vinyl-2-pyrrolidone.
4. (Currently amended) A transdermal system according to claim 1, comprising about 3-15 (m/m) 0.1 to 20% by weight, of (21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,20-dione in the matrix.
5. (Previously Presented) A transdermal system according to claim 1, wherein the matrix comprises at least one crystallization inhibitor.
6. (Previously Presented) A transdermal system according to claim 5, wherein the matrix comprises at least one N-vinyl lactam polymer.
7. (Previously Presented) A transdermal system according to claim 1, further comprising at least one-penetration enhancer.

8. (Previously Presented) A transdermal system according to claim 7, wherein said penetration enhancer is lauryl alcohol, 1,2-propanediol, or methyl ester-as well as mixtures thereof.
9. (Previously Presented) A transdermal system according to claim 1, further comprising an additional content of at least one estrogen.
10. (Previously Presented) A transdermal system according to claim 1, further comprising an additional content of at least one stabilizer.
11. (Previously Presented) A transdermal system according to claim 1, comprising 1 to 15% of (21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,20-dione in the matrix.
12. (Previously Presented) A transdermal system according to claim 6, wherein the matrix N-vinyl lactam polymer is a N-vinyl -1-aza-cycloheptan-2-one homopolymer, N-vinyl-piperidin-2-one homopolymer, a polymer of vinylpyrrolidone or a co-polymer of vinylpyrrolidone with vinyl acetate.
13. (Previously Presented) A transdermal system according to claim 12, wherein the vinylpyrrolidone is polyvinylidene.
14. (Previously Presented) A transdermal system according to claim 9, wherein said estrogen is estradiol, estriol, ethinylestradiol, or a derivative thereof.
15. (Previously Presented) A transdermal system according to claim 9, wherein said estrogen is a mono-ester or a diester.
16. (Previously Presented) A transdermal system according to claim 9, wherein said estrogen is estradiol-3,17 betadiopropionate.
17. (Previously Presented) A transdermal system according to claim 7, wherein said

penetration enhancer is a monovalent or multivalent alcohol; a saturated or unsaturated fatty alcohol with 8 to 18 carbon atoms; a hydrocarbon; a saturated or unsaturated fatty acid with 8 to 18 carbon atoms; a fatty acid ester with up to 24 carbon atoms or a dicarboxylic acid diester with up to 24 carbon atoms; a phosphatide derivative, a terpene, a urea or its derivative or ether; or diethylene glycol monoethyl ether.

18. (Previously Presented) A transdermal system according to claim 7, wherein said penetration enhancer is an isopropyl ester of myristic acid, oleic acid, diisopropyl adipate, diisopropyl sebacate, lauric acid, oleic acid, as well as mixtures thereof.

19. (Previously Presented) A transdermal system according to claim 17, wherein said monovalent or multivalent alcohol is ethanol, 1,2-propanediol or benzyl alcohol.

20. (Previously Presented) A transdermal system according to claim 17, wherein said saturated or unsaturated fatty alcohol with 8 to 18 carbon atoms is lauryl alcohol or cetyl alcohol.

21. (Previously Presented) A transdermal system according to claim 17, wherein said hydrocarbon is mineral oil.

22. (Previously Presented) A transdermal system according to claim 17, wherein said saturated and unsaturated fatty acid with 8 to 18 carbon atoms is stearic acid or oleic acid.

23. (Previously Presented) A transdermal system according to claim 17, wherein said fatty acid ester with up to 24 carbon atoms or said dicarboxylic acid diester with up to 24 carbon atoms is methyl ester, ethyl ester, isopropyl ester, butyl ester, sec-butyl ester, isobutyl ester, tert-butyl ester or monoglyceric acid ester of acetic acid, caproic acid, lauric acid, myristic acid, stearic acid, or palmitic acid.

24. (Previously Presented) A transdermal system according to claim 17, wherein said urea or its derivative or ether is dimethyl isosorbide.

25. (Previously Presented) A transdermal system according to claim 17, wherein said a phosphatide derivative is lecithin.

26. (Previously Presented) A transdermal system according to claim 10, wherein said stabilizer is beta-cyclodextrin.